-
1.发明申请公开(公告)号：US20090068155A1
公开(公告)日：2009-03-12
申请号：US12109066
申请日：2008-04-24
CPC分类号： A61K9/0043 , A61K35/28 , A61K35/30 , A61K38/47 , A61K2300/00
摘要： Methods and compositions for preventing and treating the damaged and/or degenerating CNS experiencing loss or death of CNS cells. Various embodiments of the invention transport a therapeutically effective amount of, inter alia, at least one therapeutic cell to the CNS by intranasal application to the upper-third of the nasal cavity, thereby bypassing the blood-brain barrier. A pharmaceutical composition according to the invention may comprise at least one therapeutic cell, at least one delivery-enhancement agent, at least one antibiotic, at least one regulatory factor and/or at least one immunosuppressive agent, wherein the composition is delivered to the upper-third of the nasal cavity. The therapeutic cells, once delivered to the CNS, migrate preferentially to the area of damage or degeneration or injury.
摘要翻译： 用于预防和治疗CNS细胞损伤或死亡的损伤和/或退化的CNS的方法和组合物。 本发明的各种实施方案通过鼻内施用到鼻腔上三分之一，从而绕过血脑屏障，将治疗有效量的尤其是至少一种治疗细胞转运至CNS。 根据本发明的药物组合物可以包含至少一种治疗细胞，至少一种递送增强剂，至少一种抗生素，至少一种调节因子和/或至少一种免疫抑制剂，其中所述组合物被递送至上 三分之一的鼻腔。 一旦递送到CNS的治疗细胞优先迁移到损伤或退化或损伤的区域。
-
2.发明申请METHODS, PHARMACEUTICAL COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR ADMINISTERING THERAPEUTIC CELLS TO THE ANIMAL CENTRAL NERVOUS SYSTEM 审中-公开方法，药物组合物和制剂用于动物中枢神经系统治疗治疗细胞的文章公开(公告)号：US20160206554A1
公开(公告)日：2016-07-21
申请号：US15082210
申请日：2016-03-28
CPC分类号： A61K9/0043 , A61K35/28 , A61K35/30 , A61K38/47 , A61K2300/00
摘要： Methods and compositions for preventing and treating the damaged and/or degenerating CNS experiencing loss or death of CNS cells. Various embodiments of the invention transport a therapeutically effective amount of, inter alfa at least one therapeutic cell to the CNS by intranasal application to the upper-third of the nasal cavity, thereby bypassing the blood-brain barrier. A pharmaceutical composition according to the invention may comprise at least one therapeutic cell, at least one delivery-enhancement agent, at least one antibiotic, at least one regulatory factor and/or at least one immunosuppressive agent, wherein the composition is delivered to the upper-third of the nasal cavity. The therapeutic cells, once delivered to the CNS, migrate preferentially to the area of damage or degeneration or injury.
摘要翻译： 用于预防和治疗CNS细胞损伤或死亡的损伤和/或退化的CNS的方法和组合物。 本发明的各种实施方案通过鼻内施用到鼻腔上三分之一，从而绕过血脑屏障，将治疗有效量的至少一种治疗性细胞传递至CNS。 根据本发明的药物组合物可以包含至少一种治疗细胞，至少一种递送增强剂，至少一种抗生素，至少一种调节因子和/或至少一种免疫抑制剂，其中所述组合物被递送至上 三分之一的鼻腔。 一旦递送到CNS的治疗细胞优先迁移到损伤或退化或损伤的区域。
-
3.发明授权Use of the opposite cell differentiation program (OCDP) for the treatment of degenerated organs in the pathological state 有权使用相反的细胞分化程序（OCDP）来治疗病理状态的退行性器官公开(公告)号：US09157065B2
公开(公告)日：2015-10-13
申请号：US12678446
申请日：2008-04-18
CPC分类号： C12N5/0622 , A61K35/12 , C12N2502/14
摘要： The present invention relates to a method for the treatment of organs which are degenerative and/or in the pathological state by means of the use of cells, which are phenotypically stably differentiating or differentiated but not necessarily ultimately predetermined with respect to development, from a donor organ selected according to the principles of the opposite cell differentiation program (OCDP) and also to the use of cells of this type for the treatment or for the production of a drug for treatment of the same. Furthermore, the present invention relates to pharmaceutical agents comprising suitable phenotypically stable cells, cells of a first organ which is different from the second organ with respect to organ type thereby being used, which, in the normal physiological state with respect to a predetermined set of expressed genes and/or phenotypical properties, have opposite properties to the second cells in the normal physiological state.
摘要翻译： 本发明涉及一种通过使用细胞治疗退行性和/或病理状态的器官的方法，所述细胞是表型稳定分化或分化但不一定最终预先确定来自供体 根据相反细胞分化程序（OCDP）的原理选择的器官，并且还使用这种类型的细胞用于治疗或用于治疗药物的生产。 此外，本发明涉及包含合适的表型稳定细胞的药剂，与第二器官相对于器官类型不同的第一器官的细胞，因此被使用，其在正常生理状态下相对于预定的一组 表达的基因和/或表型性质在正常生理状态下具有与第二细胞相反的特性。
-
4.发明授权公开(公告)号：US08283160B2
公开(公告)日：2012-10-09
申请号：US12109066
申请日：2008-04-24
CPC分类号： A61K9/0043 , A61K35/28 , A61K35/30 , A61K38/47 , A61K2300/00
摘要： Methods and compositions for preventing and treating the damaged and/or degenerating CNS experiencing loss or death of CNS cells. Various embodiments of the invention transport a therapeutically effective amount of, inter alia, at least one therapeutic cell to the CNS by intranasal application to the upper-third of the nasal cavity, thereby bypassing the blood-brain barrier. A pharmaceutical composition according to the invention may comprise at least one therapeutic cell, at least one delivery-enhancement agent, at least one antibiotic, at least one regulatory factor and/or at least one immunosuppressive agent, wherein the composition is delivered to the upper-third of the nasal cavity. The therapeutic cells, once delivered to the CNS, migrate preferentially to the area of damage or degeneration or injury.
摘要翻译： 用于预防和治疗CNS细胞损伤或死亡的损伤和/或退化的CNS的方法和组合物。 本发明的各种实施方案通过鼻内施用到鼻腔上三分之一，从而绕过血脑屏障，将治疗有效量的尤其是至少一种治疗细胞转运至CNS。 根据本发明的药物组合物可以包含至少一种治疗细胞，至少一种递送增强剂，至少一种抗生素，至少一种调节因子和/或至少一种免疫抑制剂，其中所述组合物被递送至上 三分之一的鼻腔。 一旦递送到CNS的治疗细胞优先迁移到损伤或退化或损伤的区域。
-
5.发明申请USE OF THE OPPOSITE CELL DIFFERENTIATION PROGRAM (OCDP) FOR THE TREATMENT OF DEGENERATED ORGANS IN THE PATHOLOGICAL STATE 有权在病理状态下使用对比细胞分化程序（OCDP）治疗变性的器官公开(公告)号：US20100278786A1
公开(公告)日：2010-11-04
申请号：US12678446
申请日：2008-04-18
IPC分类号： A61K35/407 , C12P1/00 , A61K35/12 , C12N5/07 , A61P25/16 , A61P25/28 , A61P25/00 , A61P13/12 , A61P1/16 , A61K35/36 , A61K35/39 , C12N5/079
CPC分类号： C12N5/0622 , A61K35/12 , C12N2502/14
摘要： The present invention relates to a method for the treatment of organs which are degenerative and/or in the pathological state by means of the use of cells, which are phenotypically stably differentiating or differentiated but not necessarily ultimately predetermined with respect to development, from a donor organ selected according to the principles of the opposite cell differentiation program (OCDP) and also to the use of cells of this type for the treatment or for the production of a drug for treatment of the same. Furthermore, the present invention relates to pharmaceutical agents comprising suitable phenotypically stable cells, cells of a first organ which is different from the second organ with respect to organ type thereby being used, which, in the normal physiological state with respect to a predetermined set of expressed genes and/or phenotypical properties, have opposite properties to the second cells in the normal physiological state.
摘要翻译： 本发明涉及一种通过使用细胞治疗退行性和/或病理状态的器官的方法，所述细胞是表型稳定分化或分化但不一定最终预先确定来自供体 根据相反细胞分化程序（OCDP）的原理选择的器官，并且还使用这种类型的细胞用于治疗或用于治疗药物的生产。 此外，本发明涉及包含合适的表型稳定细胞的药剂，与第二器官相对于器官类型不同的第一器官的细胞，因此被使用，其在正常生理状态下相对于预定的一组 表达的基因和/或表型性质在正常生理状态下具有与第二细胞相反的特性。
-
6.发明授权公开(公告)号：US09445991B2
公开(公告)日：2016-09-20
申请号：US15082210
申请日：2016-03-28
CPC分类号： A61K9/0043 , A61K35/28 , A61K35/30 , A61K38/47 , A61K2300/00
摘要： Methods and compositions for preventing and treating the damaged and/or degenerating CNS experiencing loss or death of CNS cells. Various embodiments of the invention transport a therapeutically effective amount of, inter alia at least one therapeutic cell to the CNS by intranasal application to the upper-third of the nasal cavity, thereby bypassing the blood-brain barrier. A pharmaceutical composition according to the invention may comprise at least one therapeutic cell, at least one delivery-enhancement agent, at least one antibiotic, at least one regulatory factor and/or at least one immunosuppressive agent, wherein the composition is delivered to the upper-third of the nasal cavity. The therapeutic cells, once delivered to the CNS, migrate preferentially to the area of damage or degeneration or injury.
摘要翻译： 用于预防和治疗CNS细胞损伤或死亡的损伤和/或退化的CNS的方法和组合物。 本发明的各种实施方案通过鼻内施用到鼻腔上三分之一，从而绕过血脑屏障，将治疗有效量的尤其是至少一种治疗细胞转运至CNS。 根据本发明的药物组合物可以包含至少一种治疗细胞，至少一种递送增强剂，至少一种抗生素，至少一种调节因子和/或至少一种免疫抑制剂，其中所述组合物被递送至上 三分之一的鼻腔。 一旦递送到CNS的治疗细胞优先迁移到损伤或退化或损伤的区域。
-
公开(公告)号：US20130028874A1
公开(公告)日：2013-01-31
申请号：US13647066
申请日：2012-10-08
IPC分类号： A61K35/30 , A61P9/10 , A61P25/28 , A61P25/16 , A61P7/02 , A61P3/00 , A61P25/14 , A61P25/08 , A61P27/12 , A61P3/02 , A61P7/06 , A61P7/04 , A61P25/00 , A61P25/18
CPC分类号： A61K9/0043 , A61K35/28 , A61K35/30 , A61K38/47 , A61K2300/00
摘要： Methods and compositions for preventing and treating the damaged and/or degenerating CNS experiencing loss or death of CNS cells. Various embodiments of the invention transport a therapeutically effective amount of, inter alia, at least one therapeutic cell to the CNS by intranasal application to the upper-third of the nasal cavity, thereby bypassing the blood-brain barrier. A pharmaceutical composition according to the invention may comprise at least one therapeutic cell, at least one delivery-enhancement agent, at least one antibiotic, at least one regulatory factor and/or at least one immunosuppressive agent, wherein the composition is delivered to the upper-third of the nasal cavity. The therapeutic cells, once delivered to the CNS, migrate preferentially to the area of damage or degeneration or injury.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.013 秒)
